UNIIQ

Type

Venture Capital

Status

Active

Location

Netherlands, The Hague

Total investments

60

Average round size

423K

Portfolio companies

59

Rounds per year

6.00

Lead investments

10

Follow on index

0.02

Areas of investment
BiotechnologySoftwareInformation TechnologyHealth CareManufacturingMedicalPharmaceuticalTherapeuticsHardwareBiopharma

Investor highlights

Industry generalist
Yes
Industry focus
GeneralistAgricultureFoodtechClimate techBiotech/Life Sciences Show 3 more
Stage focus
Seed
Geo focus
Netherlands, South Holland
Check size
Up to 350K

Data2 CTA Block

Click click! Do this trick!

Investments analytics

Last fund

Fund size
EUR 28800000

Analytics

Total investments
60
Lead investments
10
Rounds per year
6.00
Follow on index
0.02
Investments by industry
  • Biotechnology (11)
  • Information Technology (8)
  • Medical (7)
  • Health Care (6)
  • Therapeutics (5)
  • Show 75 more
Investments by region
  • The Netherlands (29)
  • Netherlands (24)
  • United States (1)
  • Canada (1)
  • France (1)
  • Show 1 more
Peak activity year
2017

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
5
Group Appearance index
0.13

Data1 Finished!

Buy stuff!

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Imuno 19 Nov 2021 Health Care, Medical, Therapeutics Seed 354K Zuid-Holland, Leiden, The Netherlands
Vortice 02 Oct 2023 Food and Beverage, Water Seed 413K South Holland, Zuid-Holland, Netherlands
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.